FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379768904> ?p ?o ?g. }

• W4379768904 endingPage "1066" @default.
• W4379768904 startingPage "1066" @default.
• W4379768904 abstract "Preoperative stereotactic radiosurgery (SRS) has been demonstrated as a feasible alternative to postoperative SRS for resectable brain metastases (BMs) with potential benefits in adverse radiation effects (AREs) and meningeal disease (MD). However, mature large-cohort multicenter data are lacking.To evaluate preoperative SRS outcomes and prognostic factors from a large international multicenter cohort (Preoperative Radiosurgery for Brain Metastases-PROPS-BM).This multicenter cohort study included patients with BMs from solid cancers, of which at least 1 lesion received preoperative SRS and a planned resection, from 8 institutions. Radiosurgery to synchronous intact BMs was allowed. Exclusion criteria included prior or planned whole-brain radiotherapy and no cranial imaging follow-up. Patients were treated between 2005 and 2021, with most treated between 2017 and 2021.Preoperative SRS to a median dose to 15 Gy in 1 fraction or 24 Gy in 3 fractions delivered at a median (IQR) of 2 (1-4) days before resection.The primary end points were cavity local recurrence (LR), MD, ARE, overall survival (OS), and multivariable analysis of prognostic factors associated with these outcomes.The study cohort included 404 patients (214 women [53%]; median [IQR] age, 60.6 [54.0-69.6] years) with 416 resected index lesions. The 2-year cavity LR rate was 13.7%. Systemic disease status, extent of resection, SRS fractionation, type of surgery (piecemeal vs en bloc), and primary tumor type were associated with cavity LR risk. The 2-year MD rate was 5.8%, with extent of resection, primary tumor type, and posterior fossa location being associated with MD risk. The 2-year any-grade ARE rate was 7.4%, with target margin expansion greater than 1 mm and melanoma primary being associated with ARE risk. Median OS was 17.2 months (95% CI, 14.1-21.3 months), with systemic disease status, extent of resection, and primary tumor type being the strongest prognostic factors associated with OS.In this cohort study, the rates of cavity LR, ARE, and MD after preoperative SRS were found to be notably low. Several tumor and treatment factors were identified that are associated with risk of cavity LR, ARE, MD, and OS after treatment with preoperative SRS. A phase 3 randomized clinical trial of preoperative vs postoperative SRS (NRG BN012) has began enrolling (NCT05438212)." @default.
• W4379768904 created "2023-06-09" @default.
• W4379768904 creator A5002225991 @default.
• W4379768904 creator A5011352112 @default.
• W4379768904 creator A5012751889 @default.
• W4379768904 creator A5016155551 @default.
• W4379768904 creator A5020788596 @default.
• W4379768904 creator A5026022894 @default.
• W4379768904 creator A5036139080 @default.
• W4379768904 creator A5040692174 @default.
• W4379768904 creator A5045014025 @default.
• W4379768904 creator A5047486082 @default.
• W4379768904 creator A5050218301 @default.
• W4379768904 creator A5054814683 @default.
• W4379768904 creator A5058440874 @default.
• W4379768904 creator A5060464914 @default.
• W4379768904 creator A5061377808 @default.
• W4379768904 creator A5073397833 @default.
• W4379768904 creator A5079216912 @default.
• W4379768904 creator A5088272637 @default.
• W4379768904 creator A5088403801 @default.
• W4379768904 creator A5089791635 @default.
• W4379768904 date "2023-08-01" @default.
• W4379768904 modified "2023-10-17" @default.
• W4379768904 title "Risk Factors for Progression and Toxic Effects After Preoperative Stereotactic Radiosurgery for Patients With Resected Brain Metastases" @default.
• W4379768904 cites W1519034510 @default.
• W4379768904 cites W1872520013 @default.
• W4379768904 cites W1985351938 @default.
• W4379768904 cites W1988566322 @default.
• W4379768904 cites W1994374489 @default.
• W4379768904 cites W2038247960 @default.
• W4379768904 cites W2038981426 @default.
• W4379768904 cites W2083128109 @default.
• W4379768904 cites W2149791601 @default.
• W4379768904 cites W2153140684 @default.
• W4379768904 cites W2401492317 @default.
• W4379768904 cites W2725029513 @default.
• W4379768904 cites W2726463501 @default.
• W4379768904 cites W2762741489 @default.
• W4379768904 cites W2897978079 @default.
• W4379768904 cites W2917491088 @default.
• W4379768904 cites W2918189147 @default.
• W4379768904 cites W2920280009 @default.
• W4379768904 cites W2980329724 @default.
• W4379768904 cites W3040100953 @default.
• W4379768904 cites W3085200879 @default.
• W4379768904 cites W3093123863 @default.
• W4379768904 cites W3165649268 @default.
• W4379768904 cites W4220999397 @default.
• W4379768904 cites W4249999102 @default.
• W4379768904 cites W4283516793 @default.
• W4379768904 cites W4288045492 @default.
• W4379768904 doi "https://doi.org/10.1001/jamaoncol.2023.1629" @default.
• W4379768904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37289451" @default.
• W4379768904 hasPublicationYear "2023" @default.
• W4379768904 type Work @default.
• W4379768904 citedByCount "3" @default.
• W4379768904 countsByYear W43797689042023 @default.
• W4379768904 crossrefType "journal-article" @default.
• W4379768904 hasAuthorship W4379768904A5002225991 @default.
• W4379768904 hasAuthorship W4379768904A5011352112 @default.
• W4379768904 hasAuthorship W4379768904A5012751889 @default.
• W4379768904 hasAuthorship W4379768904A5016155551 @default.
• W4379768904 hasAuthorship W4379768904A5020788596 @default.
• W4379768904 hasAuthorship W4379768904A5026022894 @default.
• W4379768904 hasAuthorship W4379768904A5036139080 @default.
• W4379768904 hasAuthorship W4379768904A5040692174 @default.
• W4379768904 hasAuthorship W4379768904A5045014025 @default.
• W4379768904 hasAuthorship W4379768904A5047486082 @default.
• W4379768904 hasAuthorship W4379768904A5050218301 @default.
• W4379768904 hasAuthorship W4379768904A5054814683 @default.
• W4379768904 hasAuthorship W4379768904A5058440874 @default.
• W4379768904 hasAuthorship W4379768904A5060464914 @default.
• W4379768904 hasAuthorship W4379768904A5061377808 @default.
• W4379768904 hasAuthorship W4379768904A5073397833 @default.
• W4379768904 hasAuthorship W4379768904A5079216912 @default.
• W4379768904 hasAuthorship W4379768904A5088272637 @default.
• W4379768904 hasAuthorship W4379768904A5088403801 @default.
• W4379768904 hasAuthorship W4379768904A5089791635 @default.
• W4379768904 hasConcept C126322002 @default.
• W4379768904 hasConcept C126838900 @default.
• W4379768904 hasConcept C141071460 @default.
• W4379768904 hasConcept C167135981 @default.
• W4379768904 hasConcept C2780387249 @default.
• W4379768904 hasConcept C509974204 @default.
• W4379768904 hasConcept C71924100 @default.
• W4379768904 hasConcept C72563966 @default.
• W4379768904 hasConceptScore W4379768904C126322002 @default.
• W4379768904 hasConceptScore W4379768904C126838900 @default.
• W4379768904 hasConceptScore W4379768904C141071460 @default.
• W4379768904 hasConceptScore W4379768904C167135981 @default.
• W4379768904 hasConceptScore W4379768904C2780387249 @default.
• W4379768904 hasConceptScore W4379768904C509974204 @default.
• W4379768904 hasConceptScore W4379768904C71924100 @default.
• W4379768904 hasConceptScore W4379768904C72563966 @default.
• W4379768904 hasIssue "8" @default.
• W4379768904 hasLocation W43797689041 @default.
• W4379768904 hasLocation W43797689042 @default.

• next